Insider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells 7,000 Shares of Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider David M. Chao sold 7,000 shares of Centessa Pharmaceuticals stock in a transaction on Monday, March 17th. The shares were sold at an average price of $17.17, for a total transaction of $120,190.00. Following the completion of the sale, the insider now owns 225,007 shares of the company’s stock, valued at $3,863,370.19. This represents a 3.02 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Centessa Pharmaceuticals Trading Down 2.9 %

Shares of CNTA stock opened at $16.29 on Friday. The company has a 50 day moving average of $16.46 and a 200-day moving average of $16.36. Centessa Pharmaceuticals plc has a 12-month low of $7.75 and a 12-month high of $19.09. The firm has a market cap of $2.15 billion, a P/E ratio of -10.65 and a beta of 1.54. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC boosted its holdings in shares of Centessa Pharmaceuticals by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 57,257 shares of the company’s stock worth $959,000 after acquiring an additional 660 shares during the period. GAMMA Investing LLC grew its holdings in shares of Centessa Pharmaceuticals by 29.1% during the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock worth $64,000 after purchasing an additional 865 shares in the last quarter. Atria Investments Inc grew its stake in Centessa Pharmaceuticals by 7.0% in the 3rd quarter. Atria Investments Inc now owns 17,134 shares of the company’s stock worth $274,000 after buying an additional 1,116 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in Centessa Pharmaceuticals in the fourth quarter valued at $31,000. Finally, Barclays PLC increased its position in shares of Centessa Pharmaceuticals by 1,414.9% during the 4th quarter. Barclays PLC now owns 5,302 shares of the company’s stock valued at $89,000 after purchasing an additional 4,952 shares during the last quarter. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Analyst Upgrades and Downgrades

CNTA has been the subject of a number of research reports. TD Cowen began coverage on shares of Centessa Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating for the company. Guggenheim reaffirmed a “buy” rating on shares of Centessa Pharmaceuticals in a research report on Monday, February 10th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $27.00 price objective on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Centessa Pharmaceuticals currently has an average rating of “Buy” and an average target price of $26.00.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.